GHBS
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SIRE, Christian
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
SPINO-RT, NCT06692556: Randomized Comparative Multicenter Phase III Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Not yet recruiting
3
266
Europe
Adjuvant radiotherapy
Centre Leon Berard
Cutaneous Squamous Cell Carcinoma (CSCC)
06/29
06/29
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting
3
102
Europe
Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy
UNICANCER, GORTEC, National Cancer Institute, France
Squamous Cell Carcinoma of Head and Neck
10/25
10/29
FRAIL-IMMUNE, NCT03723967: (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed
2
104
Europe
Durvalumab with Carboplatin/Paclitaxel, Combination of Durvalumab with Carboplatin/Paclitaxel
Centre Leon Berard
Squamous Cell Carcinoma of the Head and Neck
05/20
03/24
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25
STEFAN, Dinu
StrateGlio, NCT03663725 / 2018-000410-38: Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Recruiting
3
486
Europe
Intensified protocol, Stupp protocol
Centre Oscar Lambret, Association de Neuro-Oncologues d'Expression Francaise, Erasme University Hospital
Glioblastoma
05/25
11/27
BECOME-MB, NCT04074096 / 2021-006331-26: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruiting
2
10
Europe
Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Mektovi, Encorafenib Oral Capsule, Braftovi, Pembrolizumab, Keytruda
UNICANCER, European Association of Dermato Oncology, Pierre Fabre Medicament, Merck Sharp & Dohme LLC
Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
04/25
04/29
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25
ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting
N/A
250
Europe
Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
Hospices Civils de Lyon
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
12/26
12/26
CANCER-COG, NCT06036706: Neurocognitive Impact of Different Irradiation Modalities for Patients with Grade I-II Skull Base Meningioma:

Recruiting
N/A
108
Europe
Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning, Hypo-fractionated stereotactic brain irradiation, Normo-fractionated proton therapy brain irradiation, Cognitive assessment by a trained neuropsychologis
Centre Francois Baclesse, Région Normandie
Meningioma, Radiation Toxicity
09/38
06/39
HARMONIC-RT, NCT04746729: Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

Recruiting
N/A
2670
Europe
No intervention
Institut National de la Santé Et de la Recherche Médicale, France, Barcelona Institute for Global Health, The West German Proton Therapy Centre, Essen, Gustave Roussy, Cancer Campus, Grand Paris, Centre Francois Baclesse, KU Leuven, University of Aarhus, Princess Maxima Center for Pediatric Oncology, University Medical Center Groningen, Stockholm University, National Research Council, Institute of Clinical Physiology, Italy, University of Zurich, Commissariat A L'energie Atomique, Luxembourg Institute of Science and Technology, University Hospital, Essen, Aarhus University Hospital
Neoplasms
09/40
09/40
GIRARD, Edwina
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SIRE, Christian
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
SPINO-RT, NCT06692556: Randomized Comparative Multicenter Phase III Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Not yet recruiting
3
266
Europe
Adjuvant radiotherapy
Centre Leon Berard
Cutaneous Squamous Cell Carcinoma (CSCC)
06/29
06/29
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting
3
102
Europe
Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy
UNICANCER, GORTEC, National Cancer Institute, France
Squamous Cell Carcinoma of Head and Neck
10/25
10/29
FRAIL-IMMUNE, NCT03723967: (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed
2
104
Europe
Durvalumab with Carboplatin/Paclitaxel, Combination of Durvalumab with Carboplatin/Paclitaxel
Centre Leon Berard
Squamous Cell Carcinoma of the Head and Neck
05/20
03/24
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25
STEFAN, Dinu
StrateGlio, NCT03663725 / 2018-000410-38: Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Recruiting
3
486
Europe
Intensified protocol, Stupp protocol
Centre Oscar Lambret, Association de Neuro-Oncologues d'Expression Francaise, Erasme University Hospital
Glioblastoma
05/25
11/27
BECOME-MB, NCT04074096 / 2021-006331-26: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruiting
2
10
Europe
Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Mektovi, Encorafenib Oral Capsule, Braftovi, Pembrolizumab, Keytruda
UNICANCER, European Association of Dermato Oncology, Pierre Fabre Medicament, Merck Sharp & Dohme LLC
Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
04/25
04/29
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25
ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting
N/A
250
Europe
Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
Hospices Civils de Lyon
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
12/26
12/26
CANCER-COG, NCT06036706: Neurocognitive Impact of Different Irradiation Modalities for Patients with Grade I-II Skull Base Meningioma:

Recruiting
N/A
108
Europe
Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning, Hypo-fractionated stereotactic brain irradiation, Normo-fractionated proton therapy brain irradiation, Cognitive assessment by a trained neuropsychologis
Centre Francois Baclesse, Région Normandie
Meningioma, Radiation Toxicity
09/38
06/39
HARMONIC-RT, NCT04746729: Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

Recruiting
N/A
2670
Europe
No intervention
Institut National de la Santé Et de la Recherche Médicale, France, Barcelona Institute for Global Health, The West German Proton Therapy Centre, Essen, Gustave Roussy, Cancer Campus, Grand Paris, Centre Francois Baclesse, KU Leuven, University of Aarhus, Princess Maxima Center for Pediatric Oncology, University Medical Center Groningen, Stockholm University, National Research Council, Institute of Clinical Physiology, Italy, University of Zurich, Commissariat A L'energie Atomique, Luxembourg Institute of Science and Technology, University Hospital, Essen, Aarhus University Hospital
Neoplasms
09/40
09/40
GIRARD, Edwina
OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting
1/2
91
Europe
Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
Centre Francois Baclesse, National Cancer Institute, France
Malignant Gliomas, Radiotherapy, PARP Inhibitor
09/25
12/25

Download Options